Project Summary
Sub-Saharan Africa continues to bear a disproportionate burden of the global HIV epidemic. Conducting
studies in the most affected areas of the world is critical to the international HIV research agenda. The Johns
Hopkins University-Blantyre, Malawi Clinical Trials Unit (JHU Blantyre-CTU) and its clinical research site (CRS)
in Malawi, located in one of the most affected regions of the world, propose to continue and expand high-
impact research collaborations with four NIAID Clinical Research Networks in order to prevent, treat, manage
and potentially cure HIV and AIDS in adults, key populations, and children. With more than 30 years of HIV
research experience and the strong backing of the host institutions (Johns Hopkins University and College of
Medicine, University of Malawi), the CTU and CRS leadership will be responsible for the conduct and
management of clinical trials at the Blantyre, CRS in accordance with the Research Networks and NIAID
policies. The CTU aims to advance the scientific agenda of the proposed Clinical Research Networks for HIV
prevention, treatment and vaccine research among adults and children by generating hypotheses and
developing new scientific concepts; continuing implementation of active study protocols at the Blantyre CRS
under the current CTU; making available the efficient and flexible local research infrastructure to quickly
respond to emerging needs of the Networks; and by engaging protocol-specific populations. The CTU will
emphasize quality, oversight, cohesiveness and efficiency in all operations as it works to achieve these aims.
During the current CTU cycle (2013 to present), the Blantyre CRS has been involved in 35 studies at various
stages, from initiation to completion, for four existing Division of AIDS/NIAID Clinical Research Networks. The
CRS has established effective institutional and community collaborations and has been responsive to both the
Network agendas and the national health research agenda for Malawi. The goal of this application is to
describe scientific, leadership and administrative strengths of the proposed JHU-Blantyre CTU and its CRS in
Blantyre, Malawi, which will ensure successful implementation of the NIAID international clinical research
agenda. The sub-sections (A-L) of this application provide a scientific overview of the proposed CTU and
describe its administrative and financial management structures; plans for communication, evaluation and
training; and the roles, responsibilities and resources of each CTU element and CRS technical department,
including community engagement, pharmacy, laboratory, quality and regulatory assurance, and data
management. Our CTU arrangement that encompasses a single CRS has demonstrated capacity and
promotes efficiency.
Public Health Relevance Statement
Project Narrative
The Johns Hopkins University-Blantyre, Malawi Clinical Trials Unit (CTU) and its Clinical Research Site (CRS)
in Blantyre, Malawi have the expertise, experience, infrastructure and commitment to contribute to the scientific
agendas of four NIAID Clinical Research Networks. Over the past 30 years, including 13 years in the preivious
and current CTU cycle, the CRS has strong relationships with the community, in order to educate stakeholders
about the value of research and to share key findings from all studies. The CTU Principal Investigator is
strongly supported by the host institution, the Johns Hopkins University, through its leadership and a wide
array of research-related resources.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS preventionAcquired Immunodeficiency SyndromeAdolescentAdultAffectAfricaAfrica South of the SaharaAreaBasic ScienceBehavior TherapyChildChildhoodCitiesClinicalClinical ManagementClinical ResearchClinical TrialsClinical Trials Cooperative GroupClinical Trials NetworkClinical Trials UnitCollaborationsCommunicationCommunitiesCountryDataDevelopmentElementsEnsureEpidemicEthicsEvaluationGenerationsGoalsHIVHIV InfectionsHIV SeronegativityHIV SeropositivityHIV Vaccine Trials NetworkHIV prevention trials networkHIV-1HIV/AIDSHealthIndividualInformation TechnologyInfrastructureInstitutionInternationalLaboratoriesLeadershipMalawiMedicineMentorsMicrobicide Trials NetworkModalityNational Institute of Allergy and Infectious DiseaseOccupational activity of managing financesOffice of Administrative ManagementPatient Self-ReportPersonsPharmacy facilityPoliciesPopulationPrevalencePreventionPrevention ResearchPreventivePrincipal InvestigatorProphylactic treatmentProtocols documentationRegimenResearchResearch InfrastructureResearch PriorityResourcesRiskRoleScientific Advances and AccomplishmentsSiteStructureSurveysTestingTherapeutic Clinical TrialTrainingUnited States National Institutes of HealthUniversitiesVaccine ResearchVaccinesViral Load resultWorkage groupclinical research sitecollegecommunity collaborationcommunity engagementdata managementexperienceflexibilityhigh standardoperationpreventprogramsresearch studysocial interventionsstatisticssupport networktreatment researchvaccine trial
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
001910777
UEI
FTMTDMBR29C7
Project Start Date
15-February-2007
Project End Date
30-November-2027
Budget Start Date
04-June-2024
Budget End Date
30-November-2024
Project Funding Information for 2024
Total Funding
$122,800
Direct Costs
$122,800
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$122,800
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3UM1AI069518-18S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3UM1AI069518-18S1
Patents
No Patents information available for 3UM1AI069518-18S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3UM1AI069518-18S1
Clinical Studies
No Clinical Studies information available for 3UM1AI069518-18S1
News and More
Related News Releases
No news release information available for 3UM1AI069518-18S1
History
No Historical information available for 3UM1AI069518-18S1
Similar Projects
No Similar Projects information available for 3UM1AI069518-18S1